Morgan Stanley Forecasts Strong Price Appreciation for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price lifted by investment analysts at Morgan Stanley from $225.00 to $226.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the specialty pharmaceutical company’s stock. Morgan Stanley’s target price points to a potential upside of 17.93% from the stock’s current price.

Several other analysts also recently weighed in on JAZZ. Piper Sandler reaffirmed an “overweight” rating and set a $219.00 target price (up from $147.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, December 10th. Wall Street Zen upgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. TD Cowen reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a report on Thursday, January 29th. Weiss Ratings reissued a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research note on Monday, December 29th. Finally, Royal Bank Of Canada set a $194.00 price target on shares of Jazz Pharmaceuticals and gave the stock an “outperform” rating in a research note on Monday, November 17th. Fourteen research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $208.60.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock traded up $17.81 during midday trading on Wednesday, reaching $191.64. 1,912,962 shares of the stock traded hands, compared to its average volume of 1,029,824. The firm has a fifty day moving average price of $168.08 and a two-hundred day moving average price of $150.27. Jazz Pharmaceuticals has a fifty-two week low of $95.49 and a fifty-two week high of $194.83. The firm has a market cap of $11.64 billion, a price-to-earnings ratio of -31.32, a PEG ratio of 0.93 and a beta of 0.26. The company has a current ratio of 1.65, a quick ratio of 1.44 and a debt-to-equity ratio of 1.09.

Insider Activity at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 4,660 shares of the company’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $171.20, for a total transaction of $797,792.00. Following the completion of the sale, the chief accounting officer directly owned 7,012 shares of the company’s stock, valued at $1,200,454.40. This represents a 39.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $169.51, for a total value of $379,363.38. Following the completion of the transaction, the senior vice president directly owned 19,508 shares in the company, valued at $3,306,801.08. This represents a 10.29% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Royal Bank of Canada boosted its stake in Jazz Pharmaceuticals by 96.5% in the 1st quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock worth $8,394,000 after purchasing an additional 33,210 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 147.7% in the first quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock valued at $43,652,000 after purchasing an additional 209,667 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Jazz Pharmaceuticals by 4.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock worth $24,479,000 after buying an additional 7,954 shares during the period. Focus Partners Wealth boosted its position in shares of Jazz Pharmaceuticals by 3.4% in the first quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock worth $574,000 after buying an additional 154 shares during the period. Finally, Geneos Wealth Management Inc. grew its holdings in shares of Jazz Pharmaceuticals by 57.6% during the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 137 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Q4 beat — Jazz reported Q4 revenue of $1.20B and EPS of $6.64, both topping Street estimates, and closed 2025 with record total revenues of $4.3B. Press Release
• Positive Sentiment: Product momentum — Management highlighted strong commercial performance: Xywav reached $1.7B (+12% YoY), Epidiolex $1.1B (+9% YoY) and Modeyso delivered $37M in its first full quarter, supporting top-line growth. Product Highlights
• Positive Sentiment: 2026 revenue guide — Jazz issued 2026 total revenue guidance of $4.25B–$4.50B and management reiterated progress on rare-disease and oncology launches (including an expected sBLA RTOR filing for zanidatamab). This outlook is a near-term catalyst. Revenue Outlook
• Positive Sentiment: Analyst upgrade — Bank of America raised its price target to $275 and reiterated a Buy rating, signaling significant analyst upside versus current levels and likely supporting investor demand. Benzinga
• Neutral Sentiment: Investor materials posted — The full earnings call transcript and the Q4 slide deck are available for review (useful for modeling product/launch assumptions and margin drivers). Earnings Transcript Presentation
• Neutral Sentiment: Street analysis — Coverage pieces (Zacks, Seeking Alpha previews) compare metrics to estimates and highlight what to watch (oncology launches, sBLA timing) — useful but not new surprises. Zacks Analysis
• Negative Sentiment: Margin and profitability notes — Despite the beat, some filings/coverage flag a negative net margin (reported -8.86% in the quarter) and other accounting/expense dynamics that could pressure reported profitability or require clarification from management. MarketBeat Earnings Summary

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.